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Summary To test the hypothesis that steroid hormone receptor expression is particularly pronounced in
breast tumours when compared with non-neoplastic tissue, mastectomy samples were divided into 16 sectors.
Multifocal tumours, of varying receptor phenotype were found in 4 patients and in addition different regions
of large tumours also showed varying receptor contents. Remaining samples were found to consist of normal
tissue, with fat, connective tissue and some benign breast disease. In the 9 patients with oestrogen receptor
positive tumours (ER), ER content was invariably much greater in the tumours than in the remainder of the
breast. Progesterone receptor (PR) content was not closely related to ER, and was lowest in the poorly
differentiated tumours. This relation to differentiation was not seen in ER. The data support the view that
ER concentration in ER positive tumours may reflect the transformed nature of neoplastic tissue.
The significance of the presence of oestrogen and
progesterone receptors (ER & PR) in breast tumours has
been emphasized by many authors because of its
implications for the progression of the disease and its
management (Hubay et al., 1984; Seibert & Lippman, 1982).
It is less clear how the expression of receptors in tumour
relates to the incidence in normal tissue. Some studies
suggest that receptor content is greatest in malignant and
proliferative benign breast disease (Allegra et al., 1979;
Jacquemier et al., 1982) whereas in normal breast tissue ER
is virtually undetectable (Jacquemier et al., 1982; Terenius et
al., 1974). ER is raised in puberty and pregnancy but never
to levels reached in carcinoma (Israel & Band, 1984). Even
in ER positive breast cancer there is no significant binding in
the histologically normal surrounding tissue (Johansson et
al., 1970). Indeed Israel and Band (1984) developed the
hypothesis that the presence of ER in malignant disease is a
direct consequence of neoplastic transformation and
oncogene expression. This hypothesis has recently received
considerable support from the characterisation of oestrogen
receptor cDNA, which shows structural similarities to known
oncogenes (Green et al., 1986). To our knowledge, a
systematic comparison between the receptor content of a
tumour and the whole of the remainder of the breast has not
been reported. Therefore this paper reports the results
obtained from such an analysis of nine mastectomy
specimens with ER positive tumours.
Materials and methods
Patients
In all cases a preoperative attempt was made to confirm the
presence of malignancy either by aspiration cytology or by
Trucut biopsy. Where malignancy was not confirmed,
excision biopsies were performed for frozen section at the
time of mastectomy. Ischaemic time, which might affect
receptor values (Leight et al., 1984; Teichner et al., 1985),
was minimal in the operative procedure used. The breast was
left attached to the axillary structures until fully mobilised,
when it was removed between clamps and only following
sampling for receptor analysis and histology was the
required axillary procedure carried out. The removed breast
was divided into 16 equal sectors (Figure 1) and specimens
at least 1 cm3 in size were removed from the centre of each
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Figure 1 Division of mastectomy samples into 16 sectors.
sector. Grossly visible fat having been removed, the tissues
were divided into two equal halves and used respectively for
receptor assay and histological examination.
Specimens were collected from the posterior aspect of the
breast and always from medial to lateral and cranio-caudally
(i.e. Al, A2,... D4, cf. Figure 1). Collection was completed
within ten minutes following clamping.
Receptor assay
Tissue specimens were placed immediately in liquid nitrogen,
transported to the laboratory and stored in liquid nitrogen
until processed.
Tissue preparation
Low speed tumour supernatants (2000g) were prepared by
the dismembration-centrifugation method (King et al., 1979).
Briefly, frozen tissue was pulverised in a Braun
Mickrodismembrator for 70sec. The resultant powder was
resuspended in 50mm phosphate buffer (containing 30%
glycerol, 1.5mm EDTA and 10mm monothioglycerol at pH
7.4), to give protein concentrations of -2.5mgml-1, mixed
and allowed to stand for 15 min. After centrifugation
(2000g, 15min) the supernatant was used for receptor
analysis. For ER, duplicate aliquots of tissue supernatant
(100pl) were incubated with a single concentration of 3H-
oestradiol (50nM) for 18 h at 40C. Duplicate tubes were
incubated with the further addition of a 100 fold excess of
diethylstilboestrol (DES). The incubation volume was the
same in both sets of tubes. Free and bound steroid were
separated by dextran coated charcoal (DCC) extraction. A
suspension of DCC (200p1 of 0.25% charcoal 0.025%
dextran in 10mM Tris 1.5mm EDTA buffer, pH 7.4) was
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added to each tube, mixed and incubated for 10min. After
centrifugation (5min at 10,000g) portions of supernatant
(200,l) were added to 8ml liquid scintillation cocktail (4g
PPO, 0.05 g POPOP in toluene). Steroid was extracted into
the organic phase by vigorous shaking, and radioactivity
measured in a Beckman LS7500 liquid scintillation
spectrometer with correction for quenching in order to
obtain dpm. Counts from the tubes containing competitor
(non-specific binding) were subtracted from those of tubes
without competitor (total binding) to give values for
hormone specifically bound to receptor. Receptor
concentration was calculated from these values by using the
specific activity of the titrated steroid, and expressed as
fmolmg- I protein. Values were means of duplicate
estimations. For PR, similar methods were employed, with
3H-progesterone (100nM) as the labelled ligand, and
norethindrone (100 fold excess) as the unlabelled competitor.
In PR analysis, cortisol (100 fold excess) was also added to
displace the labelled ligand from transcortin. Protein
estimations (Lowry et al., 1951) were carried out with bovine
serum albumin as the standard.
Validation ofthe single saturating dose receptor assay
The single saturating dose (SSD) receptor assay has been
validated in several ways: (i) sequential estimations of ER in
a control uterine cytosol preparation gave an interassay
coefficient of variation (COV) of 17% (n=34); (ii) the intra-
assay COV was 6% (n=6); (iii) comparison between the
SSD and the Scatchard methods of ER measurement gives
an excellent correlation (r=0.97; n= 50; P<0.001; Puddefoot
et al., 1986); (iv) sequential assay of PR in uterine cytosol
preparations gave an interassay COV of 12.5% (n=33).
Shortage of suitable material and variable non-specific
binding precluded comparison between the SSD and
Scatchard methods in this case. However, quality control
exercises in which tumours were also assayed by another
laboratory gave good agreement between laboratories
(Puddefoot et al., 1986).
Histopathology
Samples were fixed in buffered formalin and processed to
paraffin in the usual way. Sections of 5gm were examined in
haematoxylin and eosin preparations.
Results
Data from 9 patients whose primary tumours were ER
positive were obtained. Of these, two were premenopausal
(cases 2 and 17, aged 38 and 49), one perimenopausal (case
6, aged 53), and the remaining six were postmenopausal
subjects aged 46-75. Oestrogen receptor data and
histological findings are illustrated in Figure 2. In all cases,
the ER content was much higher in the ER positive tumours
than in the nonmalignant specimens (see Table I). In one
case (17) three distinct tumours were all ER positive/PR
positive. In 4 patients, (cases 4, 5, 8 and 17) multifocal
tumours were detected which on subsequent analysis were
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Figure 2a-i Oestrogen receptor (ER) distribution throughout the cancerous breast and relationship to histological findings in 9
ER+ve patients. Co-ordinates (Al-D4) indicate position of sample as shown in Figure 1. Where the presenting tumour was
excised separately, its position in relation to the other samples is indicated. Values for ER content are expressed as fmolmg-1
protein. In all cases, the tumour ER content was greatly in excess of that found in the remainder of the breast. 1, tumour; E,
benign breast disease; i, fat; 1, connective tissue; OI, normal.
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Table I Tumour ER content in nine ER positive tumours,
maximum ER concentration in non-cancerous samples from the
same patients. For comparison, PR concentrations for the same
samples are also given. (cf. Figures 1, 2). Receptor concentration
values are given as fmolmg-1 protein. Bloom and Richardson
gradings are also given: w=well differentiated, m =moderate
differentiation, p =poor differentiation
Case no. 1 2 4 5 6 7 8 10 17
Age 70 38 60 64 53 59 75 46 49
ER values:
Non-tumour
tissue 36 52 10 17 18 6 21 51 22
Tumours 304 93 37 97 196 121 495 318 42
PR values:
Non-tumour
tissue 38 70 10 3 0 6 0 43 38
Tumours 37 95 20 7 62 17 303 9 34
Differentiation m m m p w p w p w
found to be distinct from each other by receptor content,
relative position or by histological criteria. Additionally,
receptor expression varied in the different regions of the
large tumours in patients 1 and 10. In case 5, two distinct
tumours were identified preoperatively on xero-
mammography. The nonmalignant tissue was by no means
homogeneous, and contained areas of benign breast disease,
as well as normal tissue. However, there were no differences
between the receptor contents of the different types of
nonmalignant tissue. PR data (Figure 3) shows no
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correlation between malignancy and receptor expression, or
indeed between ER and PR.
Using the criteria of Bloom and Richardson (1957) three
tumours were classified as well differentiated, three as
moderately differentiated and three were poorly differen-
tiated. In 4 cases, in-situ carcinoma was seen in the breast
ducts. There was no correlation between tumour grade and
ER, although the least differentiated tumours had the lowest
PR values.
Discussion
Attempts have been made to correlate ER levels with various
morphological and other criteria by which breast tumours
are classified, but these have produced variable results (for
recent review, see Seibert & Lippman, 1982). There may be
several reasons why this should be. Most importantly, it is
clear that the disease, as judged by hormone receptor
content, takes several forms. Most obvious is the well
documented recognition of at least four phenotypes for
soluble (previously termed 'cytoplasmic', Walters, 1985)
receptor status, i.e., ER positive/PR positive, ER positive/PR
negative, ER negative/PR positive, ER negative/PR negative.
Additional variants are recognised when nuclear-bound
receptors are also considered. Further evidence for
heterogeneity also emerges when receptor affinities are taken
into account (Puddefoot et al., 1986). Moreover, data
accumulated in the last few years has shown quite clearly
that such heterogeneity is even to be found in the tumour
tissue of individual patients. For example, serial samples
from an individual tumour may show extremely different
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Figure 3a-i Progesterone receptor (PR) content for the same samples as in Figure 2. Key also as in Figure 2. Values for PR
content are expressed as fmolmg - protein. The PR distribution is not closely related to ER (cf. Figure 2). In particular, the
tumour is not always relatively rich in PR compared with the remainder of the breast.
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receptor contents (Tilley et al., 1978; Braunsberg, 1975;
Silfersward et al., 1980; van Netten et al., 1985). Recently,
too, the development of monoclonal antibodies to receptors
has made possible the application of immunohistochemical
techniques which in some cases show adjacent ER positive
and ER negative tumour cells (King et al., 1985).
The present results confirm and extend these findings. One
striking observation is that patients show extraordinary
diversity in the nature of their disease. Not only do nearly
all show benign breast disease as well as cancer (Figures 2,
3) but in addition some have multiple tumours. In case 17,
all three were ER positive/PR positive, but other cases show
multifocal tumours of more than one soluble receptor
phenotype. For example, case 8 has both ER positive/PR
positive and ER positive/PR negative tumours, while case 4
has an ER positive/PR negative and an ER negative/PR
positive tumour. Case 5 combines two distinct ER
positive/PR positive tumours with, remarkably, a second
phenotype (ER negative/PR negative). This probably means
that there is no simple relationship between receptor
phenotype and oncogene expression. On the other hand, it is
very clear that in ER positive tumours, the receptor
concentration is generally vastly in excess of that found in
the remainder of the tissue (see Table I). The same
relationship is not unerringly found for PR. In some cases
PR content of PR positive tumours is higher than in the
other tissue (e.g. cases 1 and 2, see Figure 3) although
comparison with Figure 2 shows the effect is not so marked
as for ER. In other cases (e.g. 10 and 17) highest PR values
are found in non-tumour tissue. There would appear to be
no relationship between ER status and tumour
differentiation (Table I), although it is possible that poorly
differentiated tumours have low PR content.
It is obviously difficult to be sure that the material divided
between histopathologist and biochemist is always quite
homogeneous. In this connection some samples of relatively
high receptor content were found in fat or connective tissue,
(e.g. cases 1, 10, Figure 2). Here it may be suspected that the
samples were not identical, and those taken for receptor
analysis may have contained tumour cells in addition to
normal tissue.
With this caveat in mind, however, it is nevertheless clear
that the data supports the hypothesis that ER concentration
in ER positive tumours reflects the transformed function of
neoplastic tissue (Israel & Band, 1984). Following other
work (Green et al., 1986), it also suggests that the expression
of the oncogene involved may be related to ER functions.
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